The 2023 Impact of Inflammatory Bowel Disease in Canada: Cancer and IBD
Rattachement africain : ca, au. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Cancer is a major cause of morbidity and mortality among people with inflammatory bowel disease (IBD). Intestinal cancers may arise as a complication of IBD itself, while extra-intestinal cancers may arise due to some of the immunosuppressive therapies used to treat IBD. Colorectal cancer (CRC) and small bowel cancer risks remain elevated among persons with IBD as compared to age-and sex-matched members of the general population, and the lifetime risk of these cancers is strongly correlated to cumulative intestinal inflammatory burden. However, the cumulative risk of cancer, even among those with IBD is still low. Some studies suggest that IBD-CRC incidence has declined over the years, possibly owing to improved treatment standards and improved detection and management of early neoplastic lesions. Across studies of extra-intestinal cancers, there are generally higher incidences of melanoma, hepatobiliary cancer, and lung cancer and no higher incidences of breast cancer or prostate cancer, with equivocal risk of cervical cancer, among persons with IBD. While the relative risks of some extra-intestinal cancers are increased with treatment, the absolute risks of these cancers remain low and the decision to forego treatment in light of these risks should be carefully weighed against the increased risks of intestinal cancers and other disease-related complications with undertreated inflammatory disease. Quality improvement efforts should focus on optimized surveillance of cancers for which surveillance strategies exist (colorectal cancer, hepatobiliary cancer, cervical cancers, and skin cancers) and the development of cost-effective surveillance strategies for less common cancers associated with IBD.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- The 2023 Impact of Inflammatory Bowel Disease in Canada: Cancer and IBD
- Date Crossref
- 01/09/2023
- Éditeur
- Oxford University Press (OUP)
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
University of Ottawa Department of Medicine pays non établi dans la noticeUniversité ou école supérieure
-
Ottawa Hospital pays non établi dans la noticeÉtablissement de santé
-
SickKids Foundation pays non établi dans la noticeOrganisation à but non lucratif
-
Sickkids Research Institute Child Health Evaluative Sciences pays non établi dans la noticeStructure de recherche
-
University of Calgary Departments of Medicine and Community Health Sciences pays non établi dans la noticeUniversité ou école supérieure
-
McMaster University Department of Medicine pays non établi dans la noticeUniversité ou école supérieure
-
University of Toronto Mount Sinai Hospital pays non établi dans la noticeUniversité ou école supérieure
-
Public Health Ontario pays non établi dans la noticeÉtablissement de santé
-
Institute for Clinical Evaluative Sciences pays non établi dans la noticeOrganisation à but non lucratif
-
University of Manitoba IBD Clinical and Research Centre pays non établi dans la noticeUniversité ou école supérieure
-
McGill University Health Centre Division of Gastroenterology and Hepatology pays non établi dans la noticeÉtablissement de santé
-
Dalhousie University Departments of Medicine pays non établi dans la noticeUniversité ou école supérieure
Department of Medicine — University of Ottawa, Ottawa Hospital et SickKids Foundation, avec 9 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.